Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project

Cancer

Volumn 122, Issue 6, 2016, Pages 935-945

  Thompson, Daria ^a   Vo, Kieuhoa T ^a   London, Wendy B ^b   Fischer, Matthias ^c   Ambros, Peter F ^d   Nakagawara, Akira ^e   Brodeur, Garrett M ^f   Matthay, Katherine K ^a   DuBois, Steven G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^e CHIBA UNIVERSITY   (Japan)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

decision trees; gene amplification; neuroblastoma; neuroblastoma genetics; oncogene proteins genetics

Indexed keywords

FERRITIN; LACTATE DEHYDROGENASE; MYCN PROTEIN, HUMAN; N MYC PROTO ONCOGENE PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN;

ADRENAL TUMOR; ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CELLULAR PARAMETERS; CHROMOSOME 17Q; CHROMOSOME 1P; CHROMOSOME ABERRATION; CLINICAL FEATURE; DISEASE ASSOCIATION; FERRITIN BLOOD LEVEL; GENE; GENE AMPLIFICATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MITOSIS; MITOSIS KARYORRHEXIS INDEX; MYCN GENE; NEUROBLASTOMA; PRIORITY JOURNAL; STRUCTURAL CHROMOSOME ABERRATION; TUMOR DIFFERENTIATION; AGE; CANCER GRADING; FEMALE; GENETICS; INFANT; MALE; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SECONDARY; STATISTICAL MODEL;

AGE FACTORS; CHROMOSOME ABERRATIONS; FEMALE; GENE AMPLIFICATION; HUMANS; INFANT; LOGISTIC MODELS; LOSS OF HETEROZYGOSITY; MALE; N-MYC PROTO-ONCOGENE PROTEIN; NEOPLASM GRADING; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84960456450     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29848     Document Type: Article

References (35)

1. Brodeur GM, Bagatell R,. Mechanisms of neuroblastoma regression. Nat Rev Clin Oncol. 2014; 11: 704-713.
2. Ambros PF, Ambros IM, Brodeur GM, et al., International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) biology committee. BMJ Cancer. 2009; 100: 1471-1482.
3. Cohn SL, Pearson AD, London WB, et al., The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009; 27: 289-297.
4. Carlsen NL, Christensen IJ, Schroeder H, et al., Prognostic factors in neuroblastomas treated in Denmark from 1943 to 1980. A statistical estimate of prognosis based 253 cases. Cancer. 1986; 58: 2726-2735.
5. Shimada H, Ambros IM, Dehner LP, et al., The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999; 86: 364-372.
6. Brodeur GM, Seeger RC, Schwab M, et al., Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224: 1121-1124.
7. George RE, Variend S, Cullinane C, et al., Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. Med Pediatr Oncol. 2001; 36: 169-176.
8. Oppedal BR, Storm-Mathison I, Lie SO, et al., Prognostic factors in neuroblastoma: clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis. Cancer. 1988; 62: 772-780.
9. Look AT, Hayes FA, Shuster JJ, et al., Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastomas: a Pediatric Oncology Group study. J Clin Oncol. 1991; 9: 581-591.
10. Vo K, Matthay KK, Neuhaus J, et al., Clinical, biological, and prognostic differences based upon primary tumor site in neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project. J Clin Oncol. 2014; 32: 3169-3176.
11. Seeger RC, Brodeur GM, Sather H, et al., Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985; 313: 1111-1116.
12. Teshiba R, Kawano S, Wang L, et al., Age-dependent prognostic effect by mitosis-karyorrhexis index in neuroblastoma: a report from the Children's Oncology Group. Pediatr Dev Pathol. 2014; 17: 441-449.
13. Bowman LC, Castleberry RP, Cantor A, et al., Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst. 1997; 89: 373-380.
14. Fong CT, Dracopoli NC, White PS, et al., Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci U S A. 1989; 86: 3753-3757.
15. Maris JM, Guo C, Blake D, et al., Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med Pediatr Oncol. 2001; 36: 32-36.
16. Attiyeh EF, London WB, Mosse YP, et al., Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005; 353: 2243-2253.
17. Plantaz D, Vandesompele J, Van Roy N, et al., Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer. 2001; 91: 680-686.
18. Spitz R, Hero B, Simon T, et al., Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res. 2006; 12: 3368-3373.
19. Morgenstern DA, London WB, Stephens D, et al., Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: a study from the International Neuroblastoma Risk Group database. J Clin Oncol. 2014; 32: 1228-1235.
20. DuBois SG, London WB, Zhang Y, et al., Lung metastases in neuroblastoma at initial diagnosis: a report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2008; 51: 589-592.
21. Mosse YP, Deyell RJ, Berthold F, et al., Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014; 61: 627-635.
22. Cetinkaya C, Martinsson T, Sandgren J, et al., Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation. BMC Cancer. 2013; 13: 231-242.
23. London WB, Castleberry RP, Matthay KK, et al., Evidence for an age cutoff greater than 365 days for neuroblastoma risk stratification in the Children's Oncology Group. J Clin Oncol. 2005; 23: 6459-6465.
24. Shapiro DN, Valentine MB, Rowe ST, et al., Detection of N-myc gene amplification by fluorescence in situ hybridization: diagnostic utility for neuroblastoma. Am J Pathol. 1993; 142: 1339-1346.
25. Crabbe DC, Peters J, Seeger RC,. Rapid detection of MYCN gene amplification in neuroblastoma using the polymerase chain reaction. Diagn Mol Pathol. 1992; 1: 229-234.
26. Brodeur GM, Seeger RC, Barrett A, et al., International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988; 6: 1874-1881.
27. Brodeur GM, Pritchard J, Berthold F, et al., Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol. 1993; 11: 1466-1477.
28. Machin D, Cheung YB, Parmar MKB,. Survival Analysis: A Practical Approach. Chichester, England: John Wiley & Sons Inc; 2006.
29. Moroz V, Machin D, Faldum A, et al., Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group project. Eur J Cancer. 2011; 47: 561-571.
30. Cook EF, Goldman L,. Empiric comparison of multivariate analytic techniques: advantages and disadvantages of recursive partitioning techniques. J Chronic Dis. 1984; 37: 721-731.
31. Maris JM, Weiss MJ, Guo C, et al., Loss of heterozygosity as chromosome 1p36 predicts for disease progression but no decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol. 2000; 18: 1888-1899.
32. Guo C, White PS, Weiss MJ, et al., Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene. 1999; 18: 4948-4957.
33. Mosse YP, Diskin SJ, Wasserman N, et al., Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer. 2007; 46: 936-949.
34. Matthay KM, Brisse H, Couanet D, et al., Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer. 2003; 1: 155-165.
35. Taggart DR, London WB, Schmidt ML, et al., Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011; 29: 4358-4364.